influenza%20(pediatric)
INFLUENZA (PEDIATRIC)
Influenza may present as a mild respiratory illness similar to the common cold or it may present without characteristic signs and symptoms.
The main type of influenza virus are types A, B & C virus. Types A&B are the main causes of influenza outbreaks.
Patient may appear flushed and have pain on eye movement. Non-exudative pharyngitis, scattered rales or rhonchi may be present.

Antiviral Agents

  • Option for the control of influenza, but should not be used as a substitute to influenza vaccination

Prophylaxis

  • Antiviral agents (eg Oseltamivir, Zanamivir) may be used to prevent spread of influenza during an influenza outbreak in an institutionalized setting
  • May be used in persons who cannot be vaccinated due to contraindications to vaccine
    • Do not start until influenza epidemic has begun & stop only when epidemic is over
  • May be used in persons at high-risk for complications who have been vaccinated after an outbreak of influenza has begun
    • Give for 2 weeks starting from day of vaccination to give sufficient time for immunity to develop

Treatment

  • When used within 48 hours of symptom onset, antiviral agents may reduce the duration of symptoms
    • Should not be used if there is uncertainty about diagnosis or if bacterial infection cannot be ruled out
    • Administration of antiviral treatment may be considered in very ill or high-risk suspected influenza patients even without confirmed tests if:
      • Currently admitted
      • Categorized as severe, complicated, or with progressive disease
      • At high risk for complications (ie immunocompromised, <2 years of age, with comorbidities)
      • Receiving long-term Aspirin treatment
  • None of the following agents have been shown to be effective in preventing serious influenza-related complications
  • Data is limited concerning effectiveness of the antiviral agents for the treatment of patients at high-risk of serious complications of influenza

Adamantanes

  • Eg Amantadine, Rimantadine
  • Consider local resistance data when prescribing adamantanes for patients with influenza
  • Chemoprophylaxis & treatment against circulating influenza A virus strains using adamantanes are not recommended because of increasing reports of drug resistance
  • Possesses little or no activity against influenza type B virus

Baloxavir marboxil

  • The 1st approved influenza virus-specific enzyme polymerase acidic (PA) protein-targeting drug used for the treatment of acute uncomplicated seasonal influenza in patients ≥12 years old who exhibited symptoms for no more than 48 hours
  • Based on several studies, the therapeutic effect of a single dose of Baloxavir marboxil is comparable to that of the 5-day twice-daily treatment with Oseltamivir

Neuraminidase Inhibitors

  • Eg Oseltamivir, Peramivir, Zanamivir
  • Oral Oseltamivir & inhaled Zanamivir are used for treatment & prophylaxis of infection with influenza A or B viruses
    • Oral Oseltamivir is the antiviral drug of choice for the management of influenza infections in children
      • May be given to premature infants at 3-3.5 mg/kg/dose 12 hrly
    • Inhaled Zanamivir may be used in children ≥7 years old as an alternative treatment for those without any chronic lung disease
  • Recently approved intravenous Peramivir can be used for early treatment of acute uncomplicated influenza in nonhospitalized children ≥2 years of age
  • Studies are still being conducted on the use of intravenous Zanamivir for seasonal influenza but may be considered in newly emergent Oseltamivir- or Peramivir-resistant virus
  • Effects:
    • As treatment: Can reduce duration of uncomplicated influenza A & B illness by approximately 1 day compared with placebo when used within 2 days of illness onset
    • Both drugs are effective, 82% (Oseltamivir) or 84% (Zanamivir), in preventing febrile, laboratory-confirmed influenza illness in otherwise healthy individuals
  • Combination treatment with neuraminidase inhibitors is not recommended
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 13 Jan 2020
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
Stephen Padilla, 6 days ago
The Lancet Commission on Hypertension Group has recently released a position statement that contains a list of recommendations for the improvement of accuracy standards for devices that measure blood pressure (BP).